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Among several types of nanoparticles, iron-oxide-based magnetic nanoparticles (MNPs) have 
shown great potential for their use as targeted drug delivery systems [1]. Despite numerous 
advantages, some limitations of MNPs need to be overcome before their application in clinical 
practice, including ineffective spatial guidance, poor colloidal stability, usually low drug 
loading, and inadequate drug release [1,2]. 
The aim of our work was to prepare MNPs based on the controlled assembly of 
superparamagnetic iron oxide (γ-Fe2O3) nanocrystals.  Thus, we had developed a one-pot 
method for the preparation of MNPs composed of several nanocrystals, tetradecan-1-ol, 
model drug, and surfactant (Brij®L4 or our own surfactant N1,N1-dimethyl-N2-(tricosan-12-
yl)ethane-1,2-diamine (SP11)). The method is based on hot homogenization of the 
hydrophobic phase containing a nonpolar surfactant into the aqueous phase, using 
ultrasonication. The resulting MNPs showed good colloidal stability and relatively high drug 
loading capacity (up to 7.6 wt. %). The surfactant selection influenced the MNPs morphology, 
drug release profile, and MNPs surface charge, whereas the MNP size, iron oxide content, and 
drug loading were comparable among investigated formulations. 
To sum up, the specific composition gives these MNPs promising characteristics for application 
in nuclear magnetic resonance imaging and magneto-thermally-triggered targeted drug 
delivery [3,4]. They are therefore attractive candidates as novel nanotheranostics. 
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